Professor Colin Baigent
- Anaemic heart failure: factors associated with progression from severe morbidity to death among pregnant women in India
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU)
- Individual patient meta-analyses of randomized trials of aspirin for the primary prevention of cardiovascular disease (MRC PHRU)
- Medical Research Council Population Health Research Unit (MRC PHRU)
Professor of Epidemiology and Director, MRC PHRU
- Deputy Director, CTSU
Colin Baigent studied Medicine at Bristol and Oxford University (1983-89), having originally studied Mathematics at Oxford (1980-83).
He became an MRC career scientist in 2002, and in 2006 was appointed Professor of Epidemiology at Oxford. From July 2013, he became Deputy Director of CTSU.
His main interest is in cardiovascular epidemiology, and most particularly the design, conduct and application of large-scale randomised trials in cardiovascular disease. His research includes the coordination of meta-analyses of randomised trials, typically with individual participant data, resulting in landmark papers that have helped determine the effects of aspirin (and other antiplatelet drugs), non-steroidal anti-inflammatory drugs, fibrinolytic therapy, and statins in different types of patients. His group has also contributed to a better understanding of cardiovascular disease in patients with renal impairment through the Study of Heart and Renal Protection (SHARP), the largest ever in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries.
Conventional and Genetic Evidence on the Association between Adiposity and CKD.
Zhu P. et al, (2020), J Am Soc Nephrol
CONVENTIONAL AND GENETIC EVIDENCE ON THE ASSOCIATION BETWEEN ADIPOSITY AND CHRONIC KIDNEY DISEASE
HERRINGTON W. et al, (2020), Journal of the American Society of Nephrology
European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes.
Aktaa S. et al, (2020), Eur Heart J Qual Care Clin Outcomes
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England.
Mafham MM. et al, (2020), Lancet, 396, 381 - 389
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
Herrington WG. et al, (2020), Clin Kidney J, 13